Tag - DARE

Markets

Maxim ups Daré Biosciences PT to $4 from $3

Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...

January 18, 2022

Developments

Dare Bioscience publishes positive clinical findings for vaginally-administered tamoxifen

Dare Bioscience’s (NASDAQ:DARE) DARE-VVA1, a proprietary formulation of tamoxifen designed for vaginal delivery, showed significant improvements in reducing vaginal pH and dryness in patients with vulvar and vaginal...

March 19, 2019

Tag - DARE

Maxim ups Daré Biosciences PT to $4 from $3

Dare Bioscience publishes positive clinical findings for vaginally-administered tamoxifen

General

More